CAMBRIDGE — Ariad Pharmaceuticals Inc. has spent two decades in classic biotechnology start-up mode. Company scientists have labored at designing drugs and identifying diseases to target, while its investors have waited for Ariad’s first product to hit the market.

Some time soon, the perseverance may finally pay off.